REGULATED PRESS RELEASE published on 08/06/2024 at 17:34, 1 year 5 months ago Juillet 2024 Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant bioMérieux communique les informations mensuelles sur le nombre total de droits de vote et d'actions au 31/07/2024 conformément aux réglementations financières Droits De Vote BioMérieux Actions Informations Mensuelles Règlementations Financières
BRIEF published on 07/05/2024 at 15:57, 1 year 6 months ago BioMérieux : Informations sur le nombre d'actions et de droits de vote en juin 2024 Droits De Vote Capital Social BioMérieux Actions Juin 2024
BRIEF published on 07/05/2024 at 15:57, 1 year 6 months ago BioMérieux: Information on the number of shares and voting rights in June 2024 Share Capital Voting Rights BioMérieux Actions June 2024
REGULATED PRESS RELEASE published on 07/05/2024 at 15:52, 1 year 6 months ago Juin 2024 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant bioMérieux communique les informations mensuelles sur le nombre total de droits de vote et d'actions. Nombre de droits de vote théoriques : 191 135 911 Droits De Vote BioMérieux Actions Finance Informations Mensuelles
BRIEF published on 06/26/2024 at 07:06, 1 year 7 months ago BioMérieux Receives FDA Clearance and CLIA-Waiver for BIOFIRE® SPOTFIRE® R/ST Panel Mini BioMérieux FDA Clearance BIOFIRE® SPOTFIRE® CLIA-waiver PCR Test
BRIEF published on 06/26/2024 at 07:06, 1 year 7 months ago BioMérieux obtient l'autorisation pour le test BIOFIRE® SPOTFIRE® R/ST Panel Mini BioMérieux BIOFIRE SPOTFIRE 510(k) CLIA Point Of Care
REGULATED PRESS RELEASE published on 06/26/2024 at 07:01, 1 year 7 months ago bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat Panel Mini, providing fast syndromic testing solutions for healthcare professionals BioMérieux FDA Clearance Respiratory Infections BIOFIRE SPOTFIRE CLIA-waiver
REGULATED PRESS RELEASE published on 06/26/2024 at 07:01, 1 year 7 months ago bioMérieux obtient l’autorisation spéciale 510(k) et la dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini bioMérieux obtient l’autorisation spéciale 510(k) et la dérogation CLIA pour son test BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini BioMérieux Diagnostic In Vitro BIOFIRE SPOTFIRE Dérogation CLIA Autorisation Spéciale 510(k)
BRIEF published on 06/21/2024 at 08:40, 1 year 7 months ago BioMérieux Receives US FDA 510(k) Clearance for VITEK® REVEAL™ AST System BioMérieux Antimicrobial Resistance FDA Clearance Sepsis VITEK® REVEAL™
BRIEF published on 06/21/2024 at 08:40, 1 year 7 months ago BioMérieux obtient l’autorisation 510(k) de la FDA américaine pour son système d’antibiogramme VITEK® REVEAL™ FDA BioMérieux Sepsis VITEK® REVEAL™ Antibiogramme
Published on 02/05/2026 at 12:00, 18 minutes ago Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 2026
Published on 02/05/2026 at 09:05, 3 hours 13 minutes ago BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
Published on 02/05/2026 at 01:35, 10 hours 43 minutes ago Dr. Ruben Shiffman Files Early Warning Report in Respect of Greenland Resources
Published on 02/05/2026 at 00:00, 12 hours 18 minutes ago Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Published on 02/04/2026 at 22:25, 13 hours 53 minutes ago 55 North Mining Announces Flow-Through Financing
Published on 02/05/2026 at 11:47, 31 minutes ago Worthington Steel Announces Start of Acceptance Period for All-Cash Tender Offer of €11.00 per Share to Shareholders of Kloeckner & Co SE
Published on 02/05/2026 at 11:45, 32 minutes ago EQS-WpÜG: Takeover Offer / Target company: Klöckner & Co SE; Bidder: Worthington Steel GmbH
Published on 02/05/2026 at 11:30, 48 minutes ago Linde Reports Full-Year and Fourth-Quarter 2025 Results (Earnings Release Tables Attached)
Published on 02/05/2026 at 11:30, 48 minutes ago Déclaration nombre d'actions et droits de vote - 05.02.2026
Published on 02/05/2026 at 11:30, 48 minutes ago Disclosure of shares outstanding and voting rights - 05.02.2026
Published on 02/04/2026 at 18:04, 18 hours 13 minutes ago Capital et droits de vote au 31 janvier 2026
Published on 02/04/2026 at 18:04, 18 hours 13 minutes ago Total number of voting rights and shares making up the share capital at January 31, 2026
Published on 02/04/2026 at 17:45, 18 hours 33 minutes ago Information concerning the total number of voting rights and shares 2026 01 31